Ovarian cancer remains one of the most challenging malignancies to treat. Targeted
therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as one of …

Importance Cancer-related fatigue (CRF) remains one of the most prevalent and
troublesome adverse events experienced by patients with cancer during and after therapy …

PurposeTreatment with programmed cell death-1 or programmed death ligand 1 (PD-(L) 1)
inhibitors is now standard therapy for patients with lung cancer. The immunosuppressive …

Cancer-related fatigue is defined as a distressing, persistent, subjective sense of physical,
emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment …

Fatigue is one of the most common adverse effects of cancer that might persist for years after
treatment completion in otherwise healthy survivors. Cancer-related fatigue causes …

Purpose Understanding the etiology of cancer-related fatigue (CRF) is critical to identify
targets to develop therapies to reduce CRF burden. The goal of this systematic review was …

BACKGROUND The effective management of fatigue in patients with cancer requires a clear
delineation of what constitutes nontrivial fatigue. The authors defined numeric cutpoints for …

Reduction of Cancer-Related Fatigue With Dexamethasone: A Double-Blind, Randomized,
Placebo-Controlled Trial in Patients With Ad Page 1 Reduction of Cancer-Related Fatigue …

Background Erythropoiesis-stimulating agents reduce anaemia in patients with cancer and
could improve their quality of life, but these drugs might increase mortality. We therefore did …

Background Anaemia associated with cancer and cancer therapy is an important clinical
factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant …